| Literature DB >> 36135772 |
Chen Chen1, Geting Ye1, Jing Tang1, Jialin Li1, Wenbin Liu1, Li Wu1, Yuhua Long1.
Abstract
Four new polyketide compounds, including two new unique isocoumarins penicillol A (1) and penicillol B (2) featuring with spiroketal rings, two new citreoviridin derivatives citreoviridin H (3) and citreoviridin I (4), along with four known analogues were isolated from the mangrove endophytic fungus Penicillium sp. BJR-P2. Their structures were elucidated by extensive spectroscopic methods. The absolute configurations of compounds 1-4 based on electronic circular dichroism (ECD) calculations, DP4+ analysis, and single-crystal X-ray diffraction are presented. All the new compounds were evaluated for anti-inflammatory activity. An anti-inflammatory assay indicated that compound 2 inhibited lipopolysaccharide (LPS)-induced NO production in RAW 264.7 cells, with half-maximal inhibitory concentration (IC50) values of 12 μM, being more potent than the positive control, indomethacin (IC50 = 35.8 ± 5.7 μM). Docking study showed that compound 2 was perfectly docking into the active site of murine inducible nitric oxide oxygenase (iNOS) via forming multiple typical hydrogen bonds.Entities:
Keywords: Penicillium sp.; anti-inflammatory activity; isocoumarins; polyketides
Year: 2022 PMID: 36135772 PMCID: PMC9502265 DOI: 10.3390/md20090583
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 6.085
Figure 1Chemical structures of compounds 1–8.
1H (600 MHz) and 13C NMR (150 MHz) data for compounds 1 and 2.
| Position | 1 a ( | 1 a ( | 2 b ( | 2 b ( |
|---|---|---|---|---|
| 1 | 169.2, C | 167.5, C | ||
| 2 | 101.0, C | 100.6, C | ||
| 3 | 140.2, C | 138.3, C | ||
| 4 | 39.1, CH2 | 2.95, d (16.5) | 38.6, CH2 | 3.14, d (16.4) |
| 3.17, d (16.5) | 3.20, d (16.4) | |||
| 5 | 106.8, CH | 6.34, s | 107.4, CH | 6.29, s |
| 6 | 166.7, C | 166.4, C | ||
| 7 | 99.3, CH | 6.35, d (2.1) | 99.7, CH | 6.38, d (2.3) |
| 8 | 164.4, C | 164.7, C | ||
| 9 | 55.2, CH3 | 3.82, s | 55.8, CH3 | 3.84, s |
| 10 | 20.5, CH3 | 1.07, d (6.3) | 21.6, CH3 | 1.24, d (6.2) |
| 2′ | 63.0, CH | 4.39, m | 67.9, CH | 4.41, m |
| 3′ | 38.5, CH2 | 1.53, m | 47.9, CH2 | 2.29, dd |
| 1.78, m | 2.53, m | |||
| 4′ | 63.4, CH | 4.17, m | 202.5, C | |
| 5′ | 38.9, CH2 | 1.87, dd | 49.5, CH2 | 2.59, d (15.4) |
| 2.21, dt | 2.85, dd | |||
| 6′ | 104.6, C | 104.7, C | ||
| 8-OH | 11.0, s |
a Measure in MeOD-d4. b measure in CDCl3.
Figure 2Key HMBC and 1H-1H COSY correlations of 1–4.
Figure 3ORTEP representation of crystal structure of 1.
Figure 4(A) Experimental ECD spectra of compounds 1, 2, and 6. (B) Comparison between the experimental and calculated ECD spectra of 2.
Figure 5Key NOESY correlations of 1, 3, 4, and 6.
1H (600 MHz) and 13C NMR (150 MHz) data for compounds 3 and 4.
| Position | 3 b ( | 3 b ( | 4 a ( | 4 a ( |
|---|---|---|---|---|
| 2 | 80.2, CH | 4.24, q (6.4) | 78.8, CH | 4.08, q (6.4) |
| 3 | 86.3, C | 83.9, C | ||
| 4 | 78.1, CH | 3.94, s | 78.1, CH | 3.79, s |
| 5 | 84.9, C | 86.3, C | ||
| 6 | 204.7, C | 91.2, CH | 3.69, s | |
| 7 | 82.3, C | 73.3, C | ||
| 8 | 139.1, CH | 6.05, d (15.5) | 140.9, CH | 6.01, d (15.4) |
| 9 | 129.1, CH | 6.27, dd | 128.5, CH | 6.43, dd |
| 10 | 137.3, CH | 6.43, dd | 138.1, CH | 6.65, dd |
| 11 | 132.5, CH | 6.36, dd | 131.5, CH | 6.50, dd |
| 12 | 135.8, CH | 7.16, dd | 136.1, CH | 7.16, dd |
| 13 | 119.6, CH | 6.34, d (15.0) | 119.4, CH | 6.59, d (15.0) |
| 14 | 154.5, C | 154.9, C | ||
| 16 | 163.9, C | 165.4, C | ||
| 17 | 88.9, CH | 5.49, s | 88.1, CH | 5.64, s |
| 18 | 170.8, C | 172.1, C | ||
| 19 | 108.2, C | 108.8, C | ||
| 20 | 13.1, CH3 | 1.23, d (6.5) | 12.8, CH3 | 1.20, d (6.4) |
| 21 | 16.9, CH3 | 1.35, s | 12.8, CH3 | 1.22, s |
| 22 | 12.5, CH3 | 1.39, s | 26.3, CH3 | 1.30, s |
| 23 | 31.4, CH3 | 1.46, s | 12.2, CH3 | 1.32, s |
| 24 | 9.0, CH3 | 1.96, s | 7.9, CH3 | 2.02, s |
| 25 | 56.3, CH3 | 3.82, s | 56.3, CH3 | 3.92, s |
a Measure in MeOD-d4; b measure in CDCl3.
Inhibitory activities against LPS-induced NO production.
| Compound | IC50 (μM) | Inhibition Ratio at 50 μM |
|---|---|---|
|
| - | <50% |
|
| 12 | 97% |
|
| - | <50% |
|
| - | <50% |
| Indometacin a | 35.8 ± 5.7 | - |
a Indometacin was used as positive control for the test.
Figure 6(A) Docking results of the binding pose of positive drug indomethacin in iNOS. (B) Predicted binding mode of compound 2 docked into iNOS (PDB: 3E6T). (C) Predicted binding mode of compound 1 docked into iNOS. (PDB: 3E6T) (indomethacin is in green stick; compound 2 is in purple stick; compound 1 is in yellow stick; red dashed lines represent H-bonds; the amino acids involved in hydrogen bond interactions are in blue stick).